Cutaneous T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2013-01-16Clinical Trial Update: 506U78 in Treating Patients With Lymphoma [Phase 2]
Phase 2 clinical trial update on the agent 506U78 for various lymphomas; the study has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-11Clinical Trial Update: O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma [Phase 1]
Phase 1 trial evaluating O6-benzylguanine with Carmustine for Stage IA-IIA cutaneous T-cell lymphoma; the study was terminated.
-
CLINICAL_TRIALS trial_result · 2012-12-04Clinical Trial Update: Interleukin-2 in Treating Patients With Mycosis Fungoides [Phase 1]
Phase 1 trial evaluating interleukin-2 in patients with mycosis fungoides; the study has completed.
-
CLINICAL_TRIALS withdrawal · 2012-11-27Clinical Trial Update: Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma [Phase 2]
This Phase 2 trial evaluating oral LBH589 (panobinostat) in patients with Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma was t…
-
CLINICAL_TRIALS trial_result · 2012-11-27Clinical Trial Update: LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma [Phase 1]
A Phase 1 trial of LBH589 (panobinostat) in adults with advanced solid tumors or cutaneous T-cell lymphoma has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-10-24Clinical Trial Update: Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas [Phase 2]
Phase 2 trial update for Anti-Tac(Fv)-PE38 (LMB-2) in cutaneous T-cell lymphomas has been completed with results posted in 2012.
-
CLINICAL_TRIALS withdrawal · 2012-09-07Clinical Trial Update: Trial of Curcumin in Cutaneous T-cell Lymphoma Patients [Phase 2]
A Phase 2 trial of curcumin in patients with cutaneous T-cell lymphoma was withdrawn.
-
CLINICAL_TRIALS research · 2012-08-22Clinical Trial Update: Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma [NA]
The update discusses evaluating killer immunoglobulin-like receptor transcripts as a diagnostic approach for epidermotropic cutaneous T-cell…
-
CLINICAL_TRIALS trial_result · 2012-07-04Clinical Trial Update: Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) [Phase 1]
Phase I study of vorinostat (MK-0683) in cutaneous T-cell lymphoma (CTCL) completed; results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-04-20Clinical Trial Update: Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas [EARLY_Phase 1]
An early-phase 1 study of lenalidomide in relapsed and/or refractory peripheral T-cell lymphomas was terminated.
-
CLINICAL_TRIALS research · 2012-03-15Clinical Trial Update: Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma
This completed clinical trial update reports on clinical evaluations and laboratory studies conducted to understand the disease course in pa…
-
CLINICAL_TRIALS research · 2012-03-15Clinical Trial Update: Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin [NA]
This clinical trial update analyzes serum protein patterns in participants with mycosis fungoides/cutaneous T-cell lymphoma, psoriasis, or n…
-
CLINICAL_TRIALS trial_result · 2012-01-23Clinical Trial Update: Forodesine in the Treatment of Cutaneous T-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating forodesine for Cutaneous T-cell lymphoma has completed, as reported in a BioCryst-sponsored update.
-
FDA approval · 2012-01-06FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
The FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.
-
FDA approval · 2011-11-14FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Zolinza (vorinostat) by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2011-10-12Clinical Trial Update: A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies [Phase 1, Phase 2]
This completed Phase 1/2 trial evaluated the safety and preliminary efficacy of SGN-30 (brentuximab vedotin) in patients with CD30-positive …
-
FDA label_change · 2011-05-16FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for TARGRETIN (bexarotene) from Bausch Health US, LLC.
-
FDA approval · 2011-04-12FDA Approved: ISTODAX — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for Istodax (romidepsin) submitted by Celgene Corporation.
-
FDA approval · 2011-04-08FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
The FDA approved a supplemental application for TARGRETIN (bexarotene) filed by Bausch Health US, LLC.
-
CLINICAL_TRIALS research · 2010-05-28Clinical Trial Update: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma [Phase 2]
An open-label Phase 2 pilot trial evaluates lenalidomide (Revlimid) as adjuvant therapy for refractory Cutaneous T Cell Lymphoma; current st…
-
CLINICAL_TRIALS trial_result · 2010-04-23Clinical Trial Update: A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) [Phase 2]
Phase II study of single-agent romidepsin (FK228) in cutaneous T-cell lymphoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2009-12-11Clinical Trial Update: LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma [NA]
The LAMPP trial studying peripheral and cutaneous T-cell lymphoma has been terminated.
-
FDA approval · 2009-11-05FDA Approved: ISTODAX — Original Application (Celgene Corporation)
The FDA granted original approval for ISTODAX (romidepsin) to Celgene. The approval covered treatment for cutaneous T-cell lymphoma, includi…
-
FDA approval · 2009-09-23FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for ZOLINZA (vorinostat) submitted by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2009-08-14Clinical Trial Update: An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) [Phase 1]
Terminated Phase 1 study evaluating an HDAC inhibitor plus Targretin (bexarotene) in patients with cutaneous T-cell lymphoma.